儿童溃疡性直肠炎患者的临床特征和自然史:ESPGHAN儿科IBD波尔图小组的一项多中心研究。

IF 8.3 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Journal of Crohns & Colitis Pub Date : 2023-12-30 DOI:10.1093/ecco-jcc/jjad111
Noa Tal, Christos Tzivinikos, Marco Gasparetto, Daniela E Serban, Eyal Zifman, Iva Hojsak, Oren Ledder, Anat Yerushalmy Feler, Helena Rolandsdotter, Marina Aloi, Matteo Bramuzzo, Stephan Buderus, Paolo Lionetti, Lorenzo Norsa, Christoph Norden, Darja Urlep, Claudio Romano, Ron Shaoul, Christine Martinez-Vinson, Anna Karoliny, Elisabeth De Greef, Ben Kang, Eva VIčková, Patrizia Alvisi, Michal Kori, Marta Tavares, Batia Weiss, Seamus Hussey, Maria E Qamhawi, Laura M Palomino Pérez, Paul Henderson, Raj Parmar, Erasmo Miele, Firas Rinawi, Ana Lozano-Ruf, Veena Zamvar, Kaija-Leena Kolho, Dror S Shouval
{"title":"儿童溃疡性直肠炎患者的临床特征和自然史:ESPGHAN儿科IBD波尔图小组的一项多中心研究。","authors":"Noa Tal, Christos Tzivinikos, Marco Gasparetto, Daniela E Serban, Eyal Zifman, Iva Hojsak, Oren Ledder, Anat Yerushalmy Feler, Helena Rolandsdotter, Marina Aloi, Matteo Bramuzzo, Stephan Buderus, Paolo Lionetti, Lorenzo Norsa, Christoph Norden, Darja Urlep, Claudio Romano, Ron Shaoul, Christine Martinez-Vinson, Anna Karoliny, Elisabeth De Greef, Ben Kang, Eva VIčková, Patrizia Alvisi, Michal Kori, Marta Tavares, Batia Weiss, Seamus Hussey, Maria E Qamhawi, Laura M Palomino Pérez, Paul Henderson, Raj Parmar, Erasmo Miele, Firas Rinawi, Ana Lozano-Ruf, Veena Zamvar, Kaija-Leena Kolho, Dror S Shouval","doi":"10.1093/ecco-jcc/jjad111","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes.</p><p><strong>Methods: </strong>This was a retrospective study involving 37 sites affiliated with the IBD Porto Group of ESPGHAN. Data were collected from patients aged <18 years diagnosed with UP between January 1, 2016 and December 31, 2020.</p><p><strong>Results: </strong>We identified 196 patients with UP (median age at diagnosis 14.6 years [interquartile range, IQR 12.5-16.0]), with a median follow-up of 2.7 years [IQR 1.7-3.8]. The most common presenting symptoms were bloody stools [95%], abdominal pain [61%] and diarrhoea [47%]. At diagnosis, the median paediatric ulcerative colitis activity index [PUCAI] score was 25 [IQR 20-35], but most patients exhibited moderate-severe endoscopic inflammation. By the end of induction, 5-aminosalicylic acid administration orally, topically or both resulted in clinical remission rates of 48%, 48%, and 73%, respectively. The rates of treatment escalation to biologics at 1, 3, and 5 years were 10%, 22%, and 43%, respectively. In multivariate analysis, the PUCAI score at diagnosis was significantly associated with initiation of systemic steroids, or biologics, and subsequent acute severe colitis events and inflammatory bowel disease-associated admission, with a score ≥35 providing an increased risk for poor outcomes. By the end of follow-up, 3.1% of patients underwent colectomy. Patients with UP that experienced proximal disease progression during follow-up [48%] had significantly higher rates of a caecal patch at diagnosis and higher PUCAI score by the end of induction, compared to those without progression.</p><p><strong>Conclusion: </strong>Paediatric patients with UP exhibit high rates of treatment escalation and proximal disease extension.</p>","PeriodicalId":15547,"journal":{"name":"Journal of Crohns & Colitis","volume":" ","pages":"1939-1948"},"PeriodicalIF":8.3000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN.\",\"authors\":\"Noa Tal, Christos Tzivinikos, Marco Gasparetto, Daniela E Serban, Eyal Zifman, Iva Hojsak, Oren Ledder, Anat Yerushalmy Feler, Helena Rolandsdotter, Marina Aloi, Matteo Bramuzzo, Stephan Buderus, Paolo Lionetti, Lorenzo Norsa, Christoph Norden, Darja Urlep, Claudio Romano, Ron Shaoul, Christine Martinez-Vinson, Anna Karoliny, Elisabeth De Greef, Ben Kang, Eva VIčková, Patrizia Alvisi, Michal Kori, Marta Tavares, Batia Weiss, Seamus Hussey, Maria E Qamhawi, Laura M Palomino Pérez, Paul Henderson, Raj Parmar, Erasmo Miele, Firas Rinawi, Ana Lozano-Ruf, Veena Zamvar, Kaija-Leena Kolho, Dror S Shouval\",\"doi\":\"10.1093/ecco-jcc/jjad111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes.</p><p><strong>Methods: </strong>This was a retrospective study involving 37 sites affiliated with the IBD Porto Group of ESPGHAN. Data were collected from patients aged <18 years diagnosed with UP between January 1, 2016 and December 31, 2020.</p><p><strong>Results: </strong>We identified 196 patients with UP (median age at diagnosis 14.6 years [interquartile range, IQR 12.5-16.0]), with a median follow-up of 2.7 years [IQR 1.7-3.8]. The most common presenting symptoms were bloody stools [95%], abdominal pain [61%] and diarrhoea [47%]. At diagnosis, the median paediatric ulcerative colitis activity index [PUCAI] score was 25 [IQR 20-35], but most patients exhibited moderate-severe endoscopic inflammation. By the end of induction, 5-aminosalicylic acid administration orally, topically or both resulted in clinical remission rates of 48%, 48%, and 73%, respectively. The rates of treatment escalation to biologics at 1, 3, and 5 years were 10%, 22%, and 43%, respectively. In multivariate analysis, the PUCAI score at diagnosis was significantly associated with initiation of systemic steroids, or biologics, and subsequent acute severe colitis events and inflammatory bowel disease-associated admission, with a score ≥35 providing an increased risk for poor outcomes. By the end of follow-up, 3.1% of patients underwent colectomy. Patients with UP that experienced proximal disease progression during follow-up [48%] had significantly higher rates of a caecal patch at diagnosis and higher PUCAI score by the end of induction, compared to those without progression.</p><p><strong>Conclusion: </strong>Paediatric patients with UP exhibit high rates of treatment escalation and proximal disease extension.</p>\",\"PeriodicalId\":15547,\"journal\":{\"name\":\"Journal of Crohns & Colitis\",\"volume\":\" \",\"pages\":\"1939-1948\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2023-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Crohns & Colitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ecco-jcc/jjad111\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohns & Colitis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjad111","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:溃疡性直肠炎(UP)是溃疡性结肠炎儿科患者中一种不常见的表现。我们旨在描述儿童溃疡性直肠炎的临床特征和自然病史,并确定不良预后的预测因素:这是一项回顾性研究,涉及隶属于ESPGHAN IBD波尔图小组的37个研究机构。方法:这是一项回顾性研究,涉及隶属于ESPGHAN IBD波尔图小组的37个研究机构:我们发现了196名UP患者(确诊时的中位年龄为14.6岁[四分位间差为12.5-16.0]),中位随访时间为2.7年[四分位间差为1.7-3.8]。最常见的首发症状是血便[95%]、腹痛[61%]和腹泻[47%]。确诊时,小儿溃疡性结肠炎活动指数[PUCAI]的中位数为 25 [IQR 20-35],但大多数患者表现为中度-重度内镜炎症。在诱导治疗结束时,口服、外用或同时服用 5- 氨基水杨酸可使临床缓解率分别达到 48%、48% 和 73%。1年、3年和5年后升级为生物制剂治疗的比例分别为10%、22%和43%。在多变量分析中,诊断时的 PUCAI 评分与开始使用全身类固醇或生物制剂以及随后的急性重症结肠炎事件和炎症性肠病相关入院治疗显著相关,评分≥35 分会增加不良预后的风险。随访结束时,3.1%的患者接受了结肠切除术。在随访期间出现近端疾病进展的UP患者[48%]与未出现进展的患者相比,在诊断时出现盲肠补片的比例明显更高,在诱导结束时PUCAI评分也更高:结论:UP 儿童患者的治疗升级率和近端疾病扩展率都很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN.

Background and aims: Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes.

Methods: This was a retrospective study involving 37 sites affiliated with the IBD Porto Group of ESPGHAN. Data were collected from patients aged <18 years diagnosed with UP between January 1, 2016 and December 31, 2020.

Results: We identified 196 patients with UP (median age at diagnosis 14.6 years [interquartile range, IQR 12.5-16.0]), with a median follow-up of 2.7 years [IQR 1.7-3.8]. The most common presenting symptoms were bloody stools [95%], abdominal pain [61%] and diarrhoea [47%]. At diagnosis, the median paediatric ulcerative colitis activity index [PUCAI] score was 25 [IQR 20-35], but most patients exhibited moderate-severe endoscopic inflammation. By the end of induction, 5-aminosalicylic acid administration orally, topically or both resulted in clinical remission rates of 48%, 48%, and 73%, respectively. The rates of treatment escalation to biologics at 1, 3, and 5 years were 10%, 22%, and 43%, respectively. In multivariate analysis, the PUCAI score at diagnosis was significantly associated with initiation of systemic steroids, or biologics, and subsequent acute severe colitis events and inflammatory bowel disease-associated admission, with a score ≥35 providing an increased risk for poor outcomes. By the end of follow-up, 3.1% of patients underwent colectomy. Patients with UP that experienced proximal disease progression during follow-up [48%] had significantly higher rates of a caecal patch at diagnosis and higher PUCAI score by the end of induction, compared to those without progression.

Conclusion: Paediatric patients with UP exhibit high rates of treatment escalation and proximal disease extension.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Crohns & Colitis
Journal of Crohns & Colitis 医学-胃肠肝病学
CiteScore
15.50
自引率
7.50%
发文量
1048
审稿时长
1 months
期刊介绍: Journal of Crohns and Colitis is concerned with the dissemination of knowledge on clinical, basic science and innovative methods related to inflammatory bowel diseases. The journal publishes original articles, review papers, editorials, leading articles, viewpoints, case reports, innovative methods and letters to the editor.
期刊最新文献
Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis. Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn's Disease. 6-Mercaptopurine in ulcerative colitis: the potential of upfront dosing with allopurinol. Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis. Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn's Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1